Since April 2022 Neuro-Bio has had 4 peer-reviewed articles accepted. We are very proud that Neuro-Bio 2022 publications are all in the TOP 5% of journals as they have Impact Factor equal to or greater than 6. Click here to have more information...
On Thursday the 8th of December, the whole Neuro-Bio team took part in a team building experience, provided by Heather Bunney from Cegos Swiss. During the training, many interactive activities were completed by team. This helped understanding different personalities...
On Friday 28th of November Neuro-Bio’s CEO, Susan Greenfield, opens Aptamer Group’s new state-of-the-art laboratories and presented on the challenges in scientific discovery. To read the full article, click the link....
Neuro-Bio has launched a new webpage called “Allies of Neuro-Bio” in which people living with Alzheimer’s Disease and their careers can send their thoughts. Neuro-Bio will only be able to post a limited number and the page will simply be a notice board,...
Neuro-Bio’s manuscript entitled “ Characterisation of a Bioactive Peptide T14 in the Human and Rodent Substantia nigra: Implications for Neurodegenerative Disease” has been accepted for publication at the International Journal of Molecular Sciences. To read the...
On Thursday the 1st of December Neuro-Bio’s CEO, Susan Greenfield will host a webinar for the Alzheimer’s association. See information below on how to register and participate at the webinar.
